

Volker Heinemann

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3041332/volker-heinemann-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

234
papers

7,012
citations

36
h-index

82
g-index

251
ext. papers

8,735
ext. citations

4.6
avg, IF

5.71
L-index

#	Paper	IF	Citations
234	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1065-75	21.7	1169
233	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 692-700	2.2	515
232	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. <i>JAMA Oncology</i> , 2017 , 3, 194-201	13.4	409
231	nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	368
230	Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. <i>BMC Cancer</i> , 2008 , 8, 82	4.8	315
229	The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. <i>European Journal of Cancer</i> , 2017 , 70, 87-98	7.5	311
228	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology, The</i> , 2016 , 17, 1709-1719	21.7	258
227	Advances in cancer immunotherapy 2019 - latest trends. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 268	12.8	250
226	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1426-1434	21.7	246
225	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology, The</i> , 2017 , 18, 1159-1171	21.7	193
224	Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. <i>Cancer Treatment Reviews</i> , 2009 , 35, 262-71	14.4	157
223	Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). <i>European Journal of Cancer</i> , 2015 , 51, 1927-36	7.5	113
222	Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. <i>Cancer Medicine</i> , 2016 , 5, 2649-56	4.8	106
221	Systemic treatment of advanced pancreatic cancer. <i>Cancer Treatment Reviews</i> , 2012 , 38, 843-53	14.4	98
220	Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. <i>Seminars in Oncology</i> , 2002 , 29, 9-16	5.5	93
219	Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1050-8	2.2	92
218	Randomized Phase III Trial of Pegvorhialuronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3185-3194	2.2	92

217	Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3718-26	2.2	89
216	Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). <i>Gut</i> , 2013 , 62, 751-9	19.2	87
215	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 144-50	2.2	76
214	Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. <i>European Journal of Cancer</i> , 2009 , 45, 1117-1128	7.1	71
213	Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. <i>Oncolmmunology</i> , 2017 , 6, e1310358	7.2	70
212	Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial. <i>BMC Cancer</i> , 2015 , 15, 237	4.8	67
211	FOLFOXIRI Plus Panitumumab As First-Line Treatment of Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). <i>Journal of Clinical Oncology</i> , 2019 , 37, 3401-3411	2.2	67
210	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 638-648	9.7	63
209	NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. <i>International Journal of Cancer</i> , 2015 , 137, 678-85	7.5	63
208	Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients. <i>Clinica Chimica Acta</i> , 2015 , 448, 228-31	6.2	48
207	Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 445-445	2.2	48
206	Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. <i>Pancreatology</i> , 2016 , 16, 593-8	3.8	46
205	Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA3506-LBA3506	2.2	43
204	Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2017 , 140, 2134-2144	7.5	40
203	Present and future treatment of pancreatic cancer. <i>Seminars in Oncology</i> , 2002 , 29, 23-31	5.5	40
202	Brain Metastasis in Colorectal Cancer Patients: Survival and Analysis of Prognostic Factors. <i>Clinical Colorectal Cancer</i> , 2015 , 14, 281-90	3.8	39
201	Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. <i>Surgery</i> , 2015 , 158, 151-61	3.6	38
200	Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3505-3505	2.2	38

199	Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. <i>European Journal of Cancer</i> , 2014 , 50, 1855-63	7.5	36
198	Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). <i>Oncotarget</i> , 2017 , 8, 105749-105760	3.3	35
197	Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study. <i>Thrombosis Research</i> , 2017 , 157, 9-15	8.2	34
196	Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. <i>Clinica Chimica Acta</i> , 2015 , 440, 16-22	6.2	32
195	Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3506-3506	2.2	32
194	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1929-1937	2.2	28
193	Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: A Retrospective Cohort Study. <i>International Journal of Surgery</i> , 2016 , 28, 118-25	7.5	28
192	Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in Wild-Type Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 134-141	12.9	28
191	Economic evaluation of genetic screening for Lynch syndrome in Germany. <i>Genetics in Medicine</i> , 2015 , 17, 765-73	8.1	28
190	HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhialuronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 628-638	2.2	28
189	Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. <i>European Journal of Cancer</i> , 2014 , 50, 1891-9	7.5	27
188	A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development. <i>JMIR Public Health and Surveillance</i> , 2020 , 6, e19033	11.4	27
187	Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2019 , 106, 37-44	7.5	27
186	Preoperative serum markers for individual patient prognosis in stage I-III colon cancer. <i>Tumor Biology</i> , 2015 , 36, 7897-906	2.9	26
185	Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver?. <i>European Urology Focus</i> , 2020 , 6, 1097-1103	5.1	26
184	HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4073-4073	2.2	26
183	Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. <i>Visceral Medicine</i> , 2016 , 32, 178-83	2.4	25
182	Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3600-3600	2.2	24

181	Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 2585-2591	4.9	20
180	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018 , 100, 35-45	7.5	20
179	Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer. <i>Oncology</i> , 2010 , 79, 118-28	3.6	19
178	Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 355-60	8.9	18
177	Sotorasib for previously treated colorectal cancers with KRAS mutation (CodeBreak100): a prespecified analysis of a single-arm, phase 2 trial.. <i>Lancet Oncology</i> , 2021 ,	21.7	18
176	Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. <i>European Journal of Cancer</i> , 2016 , 55, 131-9	7.5	18
175	FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. <i>British Journal of Cancer</i> , 2021 , 124, 587-594	8.7	18
174	SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3502-3502	2.2	17
173	Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts. <i>World Journal of Gastroenterology</i> , 2014 , 20, 10769-77	5.6	17
172	Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2017 , 116, 1462-1469	8.7	16
171	Lessons from the coronavirus disease 2019 pandemic: Will virtual patient management reshape uro-oncology in Germany?. <i>European Journal of Cancer</i> , 2020 , 132, 136-140	7.5	16
170	Deepness of response: A quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 427-427	2.2	16
169	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. <i>European Journal of Cancer</i> , 2017 , 77, 13-20	7.5	15
168	The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance. <i>Acta Oncologica</i> , 2016 , 55, 318-28	3.2	15
167	Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system. <i>Pathology Research and Practice</i> , 2015 , 211, 601-9	3.4	14
166	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. <i>Clinical Cancer Research</i> , 2018 , 24, 784-793	12.9	14
165	LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. <i>BMC Cancer</i> , 2012 , 12, 144	4.8	13
164	Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. <i>European Journal of Cancer</i> , 2020 , 135, 1-7	7.5	12

163	Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer. <i>Clinica Chimica Acta</i> , 2014 , 430, 86-91	6.2	12
162	Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 178-178	2.2	12
161	mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3509-3509	2.2	12
160	Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). <i>Clinical Colorectal Cancer</i> , 2019 , 18, 183-191.e3	3.8	11
159	CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial. <i>European Radiology</i> , 2018 , 28, 5284-5292	8	11
158	Universal Genomic Testing: The next step in oncological decision-making or a dead end street?. <i>European Journal of Cancer</i> , 2017 , 82, 72-79	7.5	11
157	Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer. <i>International Journal of Cancer</i> , 2019 , 144, 569-581	7.5	11
156	The relevance of CT-based geometric and radiomics analysis of whole liver tumor burden to predict survival of patients with metastatic colorectal cancer. <i>European Radiology</i> , 2021 , 31, 834-846	8	11
155	The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018 , 473, 199-207	5.1	10
154	Reduced Periprocedural Analgesia After Replacement of Water for Injection with Glucose 5% Solution as the Infusion Medium for 90Y-Resin Microspheres. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1679-1684	8.9	10
153	Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. <i>Oncotarget</i> , 2017 , 8, 35193-35204	9	9
152	Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss of Heterozygosity Score. <i>Clinical Cancer Research</i> , 2021 ,	12.9	9
151	Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial. <i>International Journal of Cancer</i> , 2018 , 142, 1047-1055	7.5	8
150	Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). <i>Journal of Clinical Oncology</i> , 2021 , JCO2101332	2.2	8
149	Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306. <i>Annals of Surgical Oncology</i> , 2020 , 27, 2389-2401	3.1	7
148	Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1740-5	6.1	7
147	Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3591-3591	2.2	7
146	Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3502-3502	2.2	7

145	POLE gene hotspot mutations in advanced pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 2161-2166	4.9	7
144	Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 2077-2087	4.9	6
143	Improving post-surgical management of resected pancreatic cancer. <i>Lancet, The</i> , 2017 , 390, 847-848	4.0	6
142	Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3630-3630	2.2	6
141	Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 391-399	4.9	6
140	Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. <i>International Journal of Cancer</i> , 2017 , 141, 383-392	7.5	5
139	High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors. <i>Pharmacogenomics</i> , 2015 , 16, 1605-19	2.6	5
138	Standards and Challenges of Care for Colorectal Cancer Today. <i>Visceral Medicine</i> , 2016 , 32, 156-7	2.4	5
137	Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases. <i>European Radiology</i> , 2018 , 28, 4839-4848	8	5
136	Interventional radiological procedures in impaired function of surgically implanted catheter-port systems. <i>CardioVascular and Interventional Radiology</i> , 2001 , 24, 31-6	2.7	5
135	Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3511-3511	2.2	5
134	Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2020 , 137, 250-259	7.5	5
133	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2019 , 107, 100-114	7.5	5
132	Patients' Perspective on Digital Technologies in Advanced Genitourinary Cancers. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 76-82.e6	3.3	5
131	Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival. <i>International Journal of Cancer</i> , 2021 , 148, 1919-1927	7.5	5
130	Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer. <i>Gastric Cancer</i> , 2017 , 20, 358-367	7.6	4
129	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2018 , 18, 623-632	3.5	4
128	Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3558-3558	2.2	4

127	Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4029-4029 ^{2.2}	4
126	Safety of palliative chemotherapy in advanced pancreatic cancer. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 947-54	4.1 4
125	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2374-81	6.1 3
124	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2020 , 131, 89-97	7.5 3
123	Definition of An Optimal First-line Chemotherapy in Metastatic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003 , 81, 43-48	4.4 3
122	A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4050-4050	2.2 3
121	Association of microRNA-21 with efficacy of cetuximab in RAS wild-type patients in the FIRE-3 study (AIO KRK-0306) and microRNA-21 influence on gene expression in the EGFR signaling pathway.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3593-3593	2.2 3
120	Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study. <i>Journal of Medical Economics</i> , 2020 , 23, 448-455	2.4 3
119	Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). <i>Oncolmmunology</i> , 2020 , 9, 1806680	7.2 3
118	Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study. <i>British Journal of Cancer</i> , 2020 , 123, 1370-1376	8.7 3
117	BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1386-1395	9.7 3
116	NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 303, 1331-1345	2.5 3
115	Information, communication, and cancer patients' trust in the physician: what challenges do we have to face in an era of precision cancer medicine?. <i>Supportive Care in Cancer</i> , 2021 , 29, 2171-2178	3.9 3
114	The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab. <i>Oncotarget</i> , 2018 , 9, 30279-30288	3.3 3
113	Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. <i>Genome Medicine</i> , 2021 , 13, 116	14.4 3
112	Long-term progression-free survival in a metastatic pancreatic cancer patient treated with first-line nab-paclitaxel and gemcitabine. <i>In Vivo</i> , 2014 , 28, 1189-92	2.3 3
111	Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study. <i>BMC Cancer</i> , 2020 , 20, 155	4.8 2
110	Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate. <i>European Journal of Cancer</i> , 2018 , 95, 109-111	7.5 2

109	Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial. <i>European Journal of Radiology</i> , 2018 , 100, 124-129	4.7	2
108	Reply to G. Nasti and A. Ottaiano and to A. Avallone and A. Budillon. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1565-6	2.2	2
107	Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2017 , 21, 1775-1783	3.3	2
106	Improved early prediction of individual prognosis for patients with mCRC: Joint modeling of tumor shrinkage with volume data for PFS and OS.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3603-3603	2.2	2
105	Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4129-4129	2.2	2
104	Variations in Y chromosome-related genes and clinical outcome in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 634-634	2.2	2
103	BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3145-3145	2.2	2
102	Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS4649-TPS4649	2.2	2
101	Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 188-188	2.2	2
100	Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009 , 3, S43-7		2
99	Quantitative Imaging Biomarkers of the Whole Liver Tumor Burden Improve Survival Prediction in Metastatic Pancreatic Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
98	A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development (Preprint)		2
97	Validating the prognostic relevance of initial change in tumor size using a series of therapeutic regimens for patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 580-580	2.2	2
96	Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in RAS wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3503-3503	2.2	2
95	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	2
94	Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkz060	4.6	2
93	Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 58-66	3.3	2
92	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211020547	5.4	2

91	Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). <i>International Journal of Cancer</i> , 2022 , 150, 112-123	7.5	2
90	Evaluation of Visualization Using a 50/50 (Contrast Media/Glucose 5% Solution) Technique for Radioembolization as an Alternative to a Standard Sandwich Technique. <i>CardioVascular and Interventional Radiology</i> , 2017 , 40, 1740-1747	2.7	1
89	Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 291-300.e5	3.8	1
88	Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research. <i>BMC Cancer</i> , 2017 , 17, 374	4.8	1
87	Amphiregulin (AREG) SNP rs161511 to predict cetuximab efficacy independent of AREG mRNA levels: Data from FIRE3 (AIO KRK-0306).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3521-3521	2.2	1
86	Genetic variants of TCF7L2 and AXIN2 predict gender and tumor location-dependent clinical outcome in FIRE-3 trial: A validation study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3602-3602	2.2	1
85	TREAT-ME 1: Treatment of advanced gastrointestinal cancer in a clinical phase I/II trial with genetically modified mesenchymal stem cells.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3122-TPS3122	2.2	1
84	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcome of bevacizumab (bev)-based treatment in patients with metastatic colorectal cancer (mCRC): Results from TRIBE and FIRE3 trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3552-3552	2.2	1
83	Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 515-515	2.2	1
82	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3576-3576	2.2	1
81	Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 800-800	2.2	1
80	Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110) study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 549-549	2.2	1
79	Nintedanib versus placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: TRICC-C trialFinal results from the randomized phase II trial of the AIO.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 666-666	2.2	1
78	Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4025-4025	2.2	1
77	Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4025-4025	2.2	1
76	Neonax (AIO-PAK-0313): Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: A phase II study of the AIO Pancreatic Cancer Group.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS497-TPS497	2.2	1
75	Capecitabine (cape)-associated hand-foot skin reaction (HFS) as a clinical predictor of improved survival in patients (pts) with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3541-3541	2.2	1
74	Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA3506-LBA3506	2.2	1

73	Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study). <i>European Journal of Cancer</i> , 2020 , 137, 81-92	7.5	1
72	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021 , 150, 133-142	7.5	1
71	A still missing piece of the FIRE-3 puzzle - Authors' reply. <i>Lancet Oncology, The</i> , 2016 , 17, e516	21.7	1
70	Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3). <i>International Journal of Cancer</i> , 2021 , 149, 1935-1943	7.5	1
69	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). <i>International Journal of Cancer</i> , 2021 ,	7.5	1
68	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. <i>International Journal of Cancer</i> , 2019 , 145, 2082-2090	7.5	0
67	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.. <i>European Journal of Cancer</i> , 2022 , 163, 1-15	7.5	0
66	Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110) study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3559-3559	2.2	0
65	Optimizing the Analytical Value of Oncology-Related Data Based on an In-Memory Analysis Layer: Development and Assessment of the Munich Online Comprehensive Cancer Analysis Platform. <i>Journal of Medical Internet Research</i> , 2020 , 22, e16533	7.6	0
64	Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3048-3048	2.2	0
63	Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 245-245	2.2	0
62	Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study. <i>Anti-Cancer Drugs</i> , 2020 , 31, 856-865	2.4	0
61	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1153-1160	6.1	0
60	Routine application of next-generation sequencing testing in uro-oncology-Are we ready for the next step of personalised medicine?. <i>European Journal of Cancer</i> , 2021 , 146, 1-10	7.5	0
59	Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). <i>European Journal of Cancer</i> , 2021 , 147, 128-139	7.5	0
58	Genetic variants involved in the cGAS-STING pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3535-3535	2.2	0
57	Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). <i>European Journal of Cancer</i> , 2021 , 157, 71-80	7.5	0
56	Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.. <i>Frontiers in Oncology</i> , 2022 , 12, 751453	5.3	0

55	Response to letter entitled: Distinct metastatic patterns in colorectal cancer patients. <i>European Journal of Cancer</i> , 2017 , 77, 1-2	7.5
54	The role of germline polymorphisms in genes involved in the antioxidant system to predict the efficacy of cetuximab for patients with metastatic colorectal cancer (mCRC) enrolled in FIRE-3 trial.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 143-143	2.2
53	The role of genetic variants involved with ferroptosis regulator genes in predicting outcomes in patients (pts) with RAS-mutant metastatic colorectal cancer (mCRC): Data from MAVERICC and TRIBE trials.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 197-197	2.2
52	Efficacy of bevacizumab-based treatment in early-onset treatment-naïve metastatic colorectal cancer patients: An ARCAD database analysis.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 101-101	2.2
51	CCR5 B2 mutation and gene expression to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC phase III trials.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 170-170	2.2
50	Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3508-3508	2.2
49	Genetic variations in the 2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12107-12107	2.2
48	Genetic variation in TET3 and survival in metastatic colorectal cancer (mCRC) from FIRE-3, TRIBE, and MAVERICC clinical trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3575-3575	2.2
47	Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 594-594	2.2
46	Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 564-564	2.2
45	Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 558-558	2.2
44	Evaluation of health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC): A prospective, multicenter, open-label, double-arm trial of trifluridine/tipiracil (FTD/TPI) versus best supportive care (BSC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS726-TPS726	2.2
43	Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3541-3541	2.2
42	Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE, and MAVERICC trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3545-3545 ^{2.2}	2.2
41	Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Final results of the phase 1/2 TREAT-ME-1 trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14648-e14648 ^{2.2}	2.2
40	Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI randomized, open label, phase-2 trial (NCT03010001).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3500-3500	2.2
39	Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated with FOLFIRI + cetuximab / bevacizumab (FIRE-3 trial).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3584-3584	2.2
38	Genetic variants involved in bromodomain-containing protein 4 (BRD4) regulating pathway to predict outcomes in patients with metastatic colorectal cancer: Results from FIRE3 and MAVERICC trials.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 232-232	2.2

- 37 Genetic variants in immunogenic cell death (ICD) relating genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE and MAVERICC trials.. *Journal of Clinical Oncology*, **2020**, 38, 187-187 2.2
- 36 Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. *Journal of Clinical Oncology*, **2020**, 38, 190-190 2.2
- 35 Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status: Analysis of untreated RAS-wildtype mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).. *Journal of Clinical Oncology*, **2020**, 38, e16055-e16055 2.2
- 34 Implementing a novel method to estimate the "Burden of Therapy" (BOTH) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib vs. gemcitabine in the AIO ACCEPT trial.. *Journal of Clinical Oncology*, **2020**, 38, e16786-e16786 2.2
- 33 High amphiregulin mRNA expression is a strong prognostic biomarker with response to cetuximab in FIRE-1, CIOX, and FIRE-3.. *Journal of Clinical Oncology*, **2020**, 38, 4026-4026 2.2
- 32 AIO KRK0306, FIRE3 trial: CEA and CA19-9 influence outcome of patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving first-line therapy with FOLFIRI plus cetuximab or bevacizumab.. *Journal of Clinical Oncology*, **2014**, 32, 3592-3592 2.2
- 31 Influence of mRNA expression of epiregulin (EREG) and of amphiregulin (AREG) and RAS mutation on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).. *Journal of Clinical Oncology*, **2014**, 32, 3522-3522 2.2
- 30 Biomarker validation study: Genes involved in ubiquitin proteasome system (UPS) dependent EGFR-degradation for prediction of efficacy in metastatic colorectal cancer patients treated with cetuximab.. *Journal of Clinical Oncology*, **2014**, 32, 3571-3571 2.2
- 29 Cetuximab-induced skin rash: A molecular map relating polymorphisms, cell-adhesion, and autoimmunity.. *Journal of Clinical Oncology*, **2015**, 33, 570-570 2.2
- 28 A phase I, dose-finding study of orally administered S-1 in combination with epirubicin and oxaliplatin (EOS) in patients (pts) with advanced or metastatic gastrointestinal cancer (AGIC) and chemonaïve advanced esophagogastric cancer (AEGC).. *Journal of Clinical Oncology*, **2015**, 33, 140-140 2.2
- 27 Macrophage polarization related gene variants to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (bev) in combination with FOLFIRI.. *Journal of Clinical Oncology*, **2015**, 33, 621-621 2.2
- 26 Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and TRIBE cohorts.. *Journal of Clinical Oncology*, **2015**, 33, 3554-3554 2.2
- 25 TREAT-ME 1: Treatment of advanced gastrointestinal cancer in a clinical phase I/II trial with genetically modified mesenchymal stem cells: Clinical results of a phase I study.. *Journal of Clinical Oncology*, **2015**, 33, e13535-e13535 2.2
- 24 Treatment until progression: Data of the first-treatment population of the FIRE-3 (AIO KRK-0306) study.. *Journal of Clinical Oncology*, **2015**, 33, 3589-3589 2.2
- 23 Baseline carcinoembryonic antigen (CEA) serum levels to predict bevacizumab-based treatment response in patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving 1st-line therapy with FOLFIRI plus cetuximab or bevacizumab (AIO KRK0306, FIRE3 trial).. *Journal of Clinical Oncology*, **2015**, 33, 3581-3581 2.2
- 22 Genetic variants of kinases suppressors of Ras (KSR) to predict tumor response to first-line cetuximab in patients with mCRC: Prospective analysis in the FIRE 3 trial.. *Journal of Clinical Oncology*, **2015**, 33, 3613-3613 2.2
- 21 Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.. *Journal of Clinical Oncology*, **2015**, 33, 3585-3585 2.2
- 20 The histone deacetylase complex as a drugable target in colorectal cancer.. *Journal of Clinical Oncology*, **2015**, 33, e22200-e22200 2.2

- 19 Prognostic value of primary tumor resection in synchronous metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of first-line randomized trials from the ARCAD database.. *Journal of Clinical Oncology*, **2016**, 34, 658-658 2.2
- 18 Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the AIO KRK 0104 trial.. *Journal of Clinical Oncology*, **2012**, 30, 3588-3588 2.2
- 17 Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial.. *Journal of Clinical Oncology*, **2012**, 30, e11528-e11528 2.2
- 16 A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.. *Journal of Clinical Oncology*, **2012**, 30, TPS3641-TPS3641 2.2
- 15 Course of calcium and magnesium serum levels in cetuximab-treated patients: Relation to concurrent chemotherapy and possible predictive value.. *Journal of Clinical Oncology*, **2013**, 31, 521-521 2.2
- 14 Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104).. *Journal of Clinical Oncology*, **2013**, 31, 189-189^{2.2}
- 13 A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.. *Journal of Clinical Oncology*, **2013**, 31, TPS3124-TPS3124 2.2
- 12 Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment.. *Journal of Clinical Oncology*, **2013**, 31, 4007-4007 2.2
- 11 Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity. *Oncotarget*, **2021**, 12, 982-995 3.3
- 10 Patient-reported quality of life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Interim results of the TALLISUR study.. *Journal of Clinical Oncology*, **2021**, 39, 3526-3526 2.2
- 9 FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases: The PARLIM trial (AIO KRK 0314).. *Journal of Clinical Oncology*, **2021**, 39, 3553-3553 2.2
- 8 The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.. *Journal of Clinical Oncology*, **2021**, 39, 3581-3581 2.2
- 7 Consensus molecular subtypes and RAS status as biomarker of treatment intensity with fluoropyrimidine, bevacizumab, and irinotecan in metastatic colorectal cancer (XELAVIRI, AIO KRK 0110).. *Journal of Clinical Oncology*, **2021**, 39, 3552-3552 2.2
- 6 Treatment responses and disease dynamics in patients with untreated metastatic colorectal cancer receiving bevacizumab-based sequential versus combination chemotherapy: Analysis of a phase 3 trial (AIO KRK0110, XELAVIRI study).. *Journal of Clinical Oncology*, **2021**, 39, 3571-3571 2.2
- 5 Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111). *International Journal of Cancer*, **2021**, 148, 1428-1437 7.5
- 4 Genetic variants involved in the lipid metabolism pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC trials.. *Journal of Clinical Oncology*, **2021**, 39, 118-118 2.2
- 3 Single nucleotide polymorphisms (SNPs) in endoplasmic reticulum (ER) stress response genes to predict first-line treatment outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from the MAVERICC and FIRE-3 trials.. *Journal of Clinical Oncology*, **2021**, 39, 103-103 2.2
- 2 Polymorphisms of pluripotency transcription factors for predicting cetuximab efficacy in metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.. *Journal of Clinical Oncology*, **2021**, 39, 98-98 2.2

- 1 Strategies to successfully prevent COVID-19 outbreak in vulnerable uro-oncology patient population.. *Infection*, **2022**, 1 5.8